With the prospect of losing a third of its revenue because of patent expiration in 2014, Eli Lilly has bet big on oncology and diabetes drugs. In this video, David Williamson highlights the success so far, and the possible challenges, for Lilly's diabetes drug, dulaglutide. Type 2 diabetes is a big problem, and David says Lilly seems well positioned to benefit from its growing prevalence, although investors need to remember there will be some patent-expiration bumps along the way. Check out the video for more details.
This Big Pharma's Big Bet Is Paying Off
By Dave Williamson
-
Apr 16, 2013 at 6:04PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
NYSE: LLY
Eli Lilly and Company

Market Cap
$276B
Today's Change
(2.10%) $6.45
Current Price
$313.46
Price as of May 26, 2022, 4:00 p.m. ET
Eli Lilly is betting big, and it's working.
Stocks Mentioned

Eli Lilly and Company
LLY
$313.46
(2.10%)
$6.45

Merck & Co., Inc.
MRK
$92.31
(-1.54%)
$-1.44

Sanofi
SNY
$55.50
(-0.63%)
$0.35

AstraZeneca PLC
AZN
$66.70
(-0.17%)
$0.11

Novo Nordisk A/S
NVO
$106.60
(1.28%)
$1.35
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Our Most Popular Articles
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.